About | Free Trial

Last Update

2014-08-07T00:00:00.000Z

This profile was last updated on // .

Is this you? Claim your profile.

Wrong Janet Greeson?

Dr. Janet Greeson R. Ph.D.

Chief Executive Officer

Samaritan Pharmaceuticals Inc

Direct Phone: (702) ***-****       

Samaritan Pharmaceuticals Inc

101 Convention Center Drive Suite 310

Las Vegas, Nevada 89109

United States

Company Description

Samaritan Pharmaceuticals, Inc. (Samaritan) is an entrepreneurial biopharmaceutical company, focused on commercializing therapeutic products to relieve the suffering of patients with Alzheimer's disease, cancer, cardiovascular disease, human immunodeficie ... more

Find other employees at this company (4)

Background Information

Affiliations

Board Member
Mother Theresa

Founder
BB Strategists , Inc.

Co-Founder
The Research Works Inc

Education


Hotel/Restaurant Management
University of Michigan at Mid-Florida


Motel Hotel Management

BA

Florida Technological University

Jurist Doctorate Candidate

MA

Rollins College

MA degree
Motel Hotel Management
Rollins College , Orlando , Florida ,

MBA Candidate

University of Southern California

PhD

Columbia Pacific University

doctorate
Psychology
Columbia-Pacific University

doctorate
Psychology
Columbia-Pacific University , Mill Valley , California ,

Web References (199 Total References)


Stockupticks - Home

www.stockupticks.com [cached]

Dr. Janet Greeson, CEO of Samaritan stated, "We remain enthusiastically confident in the promise of SP01A.

...
Dr. Greeson, CEO of Samaritan Pharmaceuticals, stated, "We are completely excited about SP-233 (Caprospinol) as a totally new approach to treat Alzheimer's disease. Dr. Greeson continued, "We have been aggressively pushing to file an investigational new drug (IND) application for Caprospinol and this is one of the many milestones we have had to achieve to get there."
...
Dr. Janet Greeson, CEO of Samaritan Pharmaceuticals stated, "We are extremely pleased with our collaboration with Georgetown University, it gives us the ability to continually, build and grow, our pipeline of innovative drugs.
...
Dr. Janet Greeson - Chief Executive Officer, President and Director
Dr. Janet Greeson, Chairman, President and CEO, led the bold initiative that transformed Samaritan from a "one drug" Company to an innovative "Drug Development Pipeline" Biopharmaceutical Company. She strategically created a long-term value and growth model, with the Samaritan/Georgetown University collaboration; and intends to duplicate this growth model with other top tier Universities, as a solid strategy to continually build Samaritan's value and sustain its future profitability.
Dr. Greeson is a successful healthcare professional with over two decades of corporate experience focused on emerging growth situations, leadership development, and mergers and acquisitions. Although she has worked with Samaritan for nine years, as CEO for the past four years she has demonstrated a relentless perseverance and determination to succeed in the face of unrelenting change. She is extremely motivated and equipped to attack problems and seize realistic opportunities, with capability, courage and confidence.
Dr. Greeson is a co-inventor of 18 patent applications, and presently has nine "peer reviewed" journal publications. She is a best selling author of "It's Not What You Are Eating, It's What's Eating You"; and a renowned public speaker, whose guest appearances on numerous radio and TV Talk shows, has opened the door to tell the Samaritan story, in a concise and professional manner.
Dr. Greeson is an experienced growth "Model" developer. In the past, Dr. Greeson developed model "Addiction Rehab Programs" for the US Navy, and went on privately, to develop and grow a nationwide "inpatient treatment program model" which she later sold to Columbia/HCA (NYSE:COL).
Dr. Greeson has an eclectic past, once working with Mother Theresa and was privileged to be the U.S. Congressional Nominee for the State of Nevada in 1994, winning the primary without spending a dollar to campaign. She currently fulfills her altruistic energies with the Samaritan Innovative Science Foundation.
Dr. Greeson holds a BA, from Florida Technological University 1978; an MA from Rollins College 1979; a PhD from Columbia Pacific University 1987.
Dr. Greeson devotes substantially all of her time to the affairs of Samaritan Pharmaceuticals.


Stockupticks - Home

www.stockupticks.com [cached]

Although it is early stage, each preclinical study we accomplish gives us hope that we might have an extraordinary treatment for the mind robbing disease of Alzheimer's," stated Dr. Greeson, CEO of Samaritan.

...
Dr. Janet Greeson, CEO of Samaritan stated, "We remain enthusiastically confident in the promise of SP01A.
...
Dr. Greeson, CEO of Samaritan Pharmaceuticals, stated, "We are completely excited about SP-233 (Caprospinol) as a totally new approach to treat Alzheimer's disease. Dr. Greeson continued, "We have been aggressively pushing to file an investigational new drug (IND) application for Caprospinol and this is one of the many milestones we have had to achieve to get there."
...
Dr. Janet Greeson, CEO of Samaritan Pharmaceuticals stated, "We are extremely pleased with our collaboration with Georgetown University, it gives us the ability to continually, build and grow, our pipeline of innovative drugs.


Stockupticks - Home

www.stockupticks.com [cached]

Dr. Greeson, CEO of Samaritan Pharmaceuticals stated, "Clinically SP-01A has always been tested in concert with other antiretroviral drugs, this is the first time it was tested alone. We are very encouraged with the results and look forward to developing SP-01A to hopefully be the first orally administered entry cell inhibitor drug with a 'firewall' mechanism of action. Dr. Greeson went on to say, "We started our Phase II 28-day monotherapy study and we are continuing to enroll patients.

...
Dr. Janet Greeson, CEO of Samaritan stated, "Completing this 10 day HIV monotherapy study of SP01A is a significant milestone in its clinical development.
...
Dr. Janet Greeson, CEO of Samaritan stated, "We remain enthusiastically confident in the promise of SP01A.


Zurich 2007 Speakers

www.sachsforum.com [cached]

Dr Janet Greeson, Chief Executive Officer, Samaritan Pharmaceuticals


Samaritan Pharma Retains The Investor Relations Group of New York

www.samaritanpharma.com [cached]

Dr. Janet Greeson, CEO of Samaritan Pharmaceuticals commented, "We have made substantial accomplishments in developing our clinical development pipeline, as well as establishing numerous collaborative relationships with specialty pharmaceutical companies to market and sell their approved prescription drugs in Greece and Eastern Europe. As we move forward with our growth strategy, we feel the timing is right for The Investor Relations Group to play an integral role in communicating Samaritan's message to the investment community and the media-at-large.''

"...As we move forward with our growth strategy, we feel the timing is right for The Investor Relations Group to play an integral role in communicating Samaritan's message to the investment community and the media-at-large.''
Dr. Janet Greeson CEO Samaritan Pharmaceuticals
...
Audio Interview with Dr. Janet Greeson
...
Audio Interview with Dr. Janet Greeson
...
Audio Interview with Dr. Janet Greeson
...
Audio Interview with Dr. Janet Greeson
Samaritan Pharma Completes Acquisition of Metastatin Pharmaceuticals

Similar Profiles

Other People with this Name

Other people with the name Greeson

Don Greeson
Beverly-Hanks & Associates REALTORS

Wesley Greeson
International Paper Company

Chris Greeson
Illinois Department of Transportation

Cindy Greeson
Stellar Therapy Services

Lauren Greeson
American Red Cross

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory